To compare between two groups of female schizophrenia patients on the basis of blood parameters that of inflammatory markers after giving medication for schizophrenia and to see its effect on the blood parameters of inflammation.

Role of Second generation antipsychotic on level of inflammatory markers in female Schizophrenia patients-A Comparative study. - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/074405

Enrollment

Registered

2024-09-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F200- Paranoid schizophrenia

Interventions

Intervention1: Drug-second generation antipsychotic olanzapine and risperidone: Two groups of females diagnosed with schizophrenia according to ICD-11 and DSM-5 will be given second generation antip

before and after the antipsychotic treatment.

Eligibility

Inclusion criteria

Inclusion criteria: 1.All females cases fulfilling the diagnosis of schizophrenia according to criteria of ICD 11 and DSM-5. 2.Schizophrenia patients (female) who have been off psychotropic medication voluntarily or drug naive patients. 3.Age group 18-45years 4.Patient giving informed consent.

Exclusion criteria

Exclusion criteria: 1.Male schizophrenia patients. 2.Schizoaffective diagnosed cases. 3.Patients not giving informed consent. 4.History of any other neurodegenerative disorder. 5.History of epilepsy and head injury. 6.History of recent steroid use or iron supplement. 7.Female schizophrenia patients with increased triglycerides and blood sugar.

Design outcomes

Primary

Measure	Time frame
To measure the inflammatory markers like IL-6 CRP Serum Ferritin in female schizophrenia patients and its relation with Schizophrenia.Timepoint: 6 weeks	—

Secondary

Measure	Time frame
To measure the inflammatory markers IL-6 CRP Serum Ferritin after treatment with antipsychotics.Timepoint: 6 weeks after treatment with antipsychotics.	—

Countries

India

Contacts

Public ContactDr RINCHEN CHOPHEL BHUTIA

Institute of psychiatry IPGME&R SSKM hospital

drparomitaraysom@gmail.com9474550183

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026